IPA is chosen after thorough evaluation of major pathway analysis platforms.
REDWOOD CITY, CA – OCT. 24, 2006 – Ingenuity Systems announced a global licensing deal to provide the central pathways analysis platform for AstraZeneca’s global research and development programs. Ingenuity Pathway Analysis (IPA) software was chosen after a comprehensive evaluation of several major pathway analysis products.
“The need for pathways solutions is fundamental to our research and development efforts so for the past year, seven AstraZeneca sites in three countries thoroughly tested leading pathway analysis solutions based on stringent requirements,” commented Adriano Henney, Director, Discovery Enabling Capabilities and Sciences, AstraZeneca. “IPA had superior depth and quality of content and provided the most relevant functionality that was easy to use across multiple therapeutic areas of interest. IPA was the considered choice to meet our needs.”
“Pathways analysis is a fundamental part of most R&D processes and with the addition of AstraZeneca as a customer, IPA is now used by all major pharmaceutical companies in the world,” stated Jake Leschly, President and Chief Executive Officer. “AstraZeneca has a strong commitment and vision for pathways analysis and we look forward to partnering with them to enable and extend the use of IPA into their global R&D programs.”
IPA is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
IPA is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at www.ingenuity.com/trial/start.html.
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.